Why Novo Nordisk Stock Popped After Earnings

GLP-1 drugmaker Novo Nordisk's (NYSE: NVO) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning.

Novo reported smaller-than-expected Q1 sales and lowered its forecast for the rest of the year. Investors seem more interested in comments about the chances Wegovy sales will improve later this year through the company's partnership with Hims & Hers Health (NYSE: HIMS) as other GLP-1 compounders are driven out of the market.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

Novo Nordisk Q1 earnings

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 billion DKK ($11.9 billion). Net income for the quarter rose 14% to 29 billion DKK ($4.4 billion). According to S&P Global Market Intelligence data, that works out to $0.95 per share.

The growth rate in Q1 was good, but management lowered its forecast for the rest of this year "due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US."

Is Novo Nordisk stock a buy?

Management now forecasts sales growth in the 13%-21% range this year. It says operating profits will grow faster at 16%-24%. And of course, Novo Nordisk stock itself currently sells for 19.3 times trailing earnings.

At a midpoint expected growth rate of 20%, that seems an attractive valuation, yielding a PEG ratio of just under 1.0. Throw in a tidy 2.4% dividend yield, and the prospect for market share gains through the company's partnership with Hims & Hers, and I continue to see Novo Nordisk as the best value play in GLP-1 weight-loss drugs.

Should you invest $1,000 in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $695,897!*

Now, it’s worth noting Stock Advisor’s total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of May 5, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.